BIOTECanada congratulates CPHA on 100 years of leadership in public health

As a community partner of the Canadian Public Health Association, BIOTECanada, on behalf of Canada's biotechnology industry, congratulates the CPHA on 100 years of leadership in public health.

“Biotech firms are on the forefront of new treatments and technologies - like vaccines - which have lasting impacts on improving public health Canada-wide. Working in partnership with organizations like CPHA will help us improve health outcomes for all Canadians.”

"We are pleased to be a community partner and support the important work CPHA does to keep Canadians healthy," said President and CEO of BIOTECanada, Peter A. Brenders. "Biotech firms are on the forefront of new treatments and technologies - like vaccines - which have lasting impacts on improving public health Canada-wide. Working in partnership with organizations like CPHA will help us improve health outcomes for all Canadians."

Vaccines are a key biotech tool in the fight to improve public health. Immunization is a cornerstone of Canada's health system, preventing millions of cases of infectious disease. Through BIOTECanada's Vaccine Industry Committee, BIOTECanada continues to champion innovation in vaccine technology and long-term funding for immunization programs for all Canadians. Read our innovative white paper series for the history of the legacy of vaccines in Canada, available at www.biotech.ca/vaccines

BIOTECanada VIC members Mark Lievonen (President, Sanofi-Pasteur Canada), Andy Potter (CEO and Director, VIDO) and Marise Lemieux (Pfizer, and Chair, BIOTECanada Vaccine Industry Committee) will be speaking throughout the conference to highlight the value immunization brings to our continued health. Consult the program for details.

Among other public health achievements championed by the CPHA, BIOTECanada joins the association in celebrating:

• Controlling infectious disease: biotech companies are on the forefront of developing solutions to combat and control infectious disease including influenza, HIV/AIDS, respiratory diseases and more.
• Universal policies: Canada's universal health care provides care to many in our society. Biotech firms are creating products for rare diseases that need to be universally included under our system to extend the benefits of health innovation to all Canadians.